<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00130078</url>
  </required_header>
  <id_info>
    <org_study_id>9784</org_study_id>
    <nct_id>NCT00130078</nct_id>
  </id_info>
  <brief_title>Trial of SAVVY Vaginal Gel and HIV in Nigeria</brief_title>
  <official_title>Randomized Controlled Trial of SAVVY and HIV in Nigeria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biosyn</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>FHI 360</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>United States Agency for International Development (USAID)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Biosyn</source>
  <brief_summary>
    <textblock>
      Heterosexual contact is now the primary route of transmission for HIV worldwide. This study
      is a phase 3 trial designed to determine the effectiveness and safety of the 1.0% C31G
      (SAVVY) vaginal gel for the prevention of male-to-female transmission of HIV among women at
      high risk.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heterosexual contact is now the primary route of transmission for HIV worldwide. This study
      is a phase 3 multi-center, fully-masked, randomized, placebo controlled trial designed to
      determine the effectiveness and safety of the 1.0% C31G (SAVVY) vaginal gel for the
      prevention of male-to-female transmission of HIV among women at high risk.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2004</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combined incidence of HIV-1 and HIV-2</measure>
  </primary_outcome>
  <enrollment>2142</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1.0% C31G SAVVY vaginal gel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 to 35 year old women

          -  HIV negative

          -  More than one sexual partner in past 3 months

          -  Average 3 coital acts per week

          -  Willing to use vaginal gel and condoms for 12 months

        Exclusion Criteria:

          -  HIV positive

          -  Pregnant
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Feldblum</last_name>
    <role>Study Chair</role>
    <affiliation>FHI 360</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paul Feldblum</last_name>
    <phone>919 544-7040</phone>
    <phone_ext>237</phone_ext>
    <email>pfeldblum@fhi.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Medical Microbiology &amp; Parasitology, College of Medicine, University of Ibadan</name>
      <address>
        <city>Ibadan</city>
        <country>Nigeria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rasheed A Bakare, MBBS,FWACP</last_name>
    </contact>
    <investigator>
      <last_name>Rasheed A Bakare, MBBS,FWACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nigerian Institute of Medical Research</name>
      <address>
        <city>Lagos</city>
        <country>Nigeria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adesina Adeiga, DVM, MSc</last_name>
    </contact>
    <investigator>
      <last_name>Adesina Adeiga, DVM, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Nigeria</country>
  </location_countries>
  <verification_date>August 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2005</study_first_submitted>
  <study_first_submitted_qc>August 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2005</study_first_posted>
  <last_update_submitted>September 22, 2005</last_update_submitted>
  <last_update_submitted_qc>September 22, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2005</last_update_posted>
  <keyword>HIV Seronegativity</keyword>
  <keyword>HIV transmission</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

